1 Table of Contents 1 Table of Contents 4 1.1 List of Tables 5 1.2 List of Figures 7 2 Introduction 9 2.1 Transplant Complications Report Coverage 9 2.2 Graft Versus Host Disease (GVHD) - Overview 9 2.3 Liver Transplant Rejection - Overview 9 2.4 Kidney Transplant Rejection - Overview 9 2.5 Lung Transplant Rejection - Overview 9 3 Therapeutics Development 10 3.1 Graft Versus Host Disease (GVHD) 10 3.2 Liver Transplant Rejection 23 3.3 Kidney Transplant Rejection 27 3.4 Lung Transplant Rejection 34 4 Therapeutics Assessment 37 4.1 Graft Versus Host Disease (GVHD) 37 4.2 Liver Transplant Rejection 47 4.3 Kidney Transplant Rejection 53 4.4 Lung Transplant Rejection 60 5 Companies Involved in Therapeutics Development 66 5.1 Graft Versus Host Disease (GVHD) 66 5.2 Liver Transplant Rejection 98 5.3 Kidney Transplant Rejection 100 5.4 Lung Transplant Rejection 112 6 Dormant Projects 116 6.1 Graft Versus Host Disease (GVHD) 116 6.2 Liver Transplant Rejection 122 6.3 Kidney Transplant Rejection 123 6.4 Lung Transplant Rejection 126 7 Discontinued Products 127 7.1 Graft Versus Host Disease (GVHD) 127 7.2 Liver Transplant Rejection 128 7.3 Kidney Transplant Rejection 128 8 Product Development Milestones 129 8.1 Graft Versus Host Disease (GVHD) 129 8.2 Liver Transplant Rejection 145 8.3 Kidney Transplant Rejection 148 8.4 Lung Transplant Rejection 162 9 Appendix 172 9.1 Methodology 172 9.2 Coverage 172 9.3 Secondary Research 172 9.4 Primary Research 172 9.5 Expert Panel Validation 172 9.6 Contact Us 172 9.7 Disclaimer 173

1.1 List of Tables Table 1: Number of Products under Development for Graft Versus Host Disease (GVHD) 10 Table 2: Number of Products under Development by Companies, Graft Versus Host Disease (GVHD) 12 Table 3: Number of Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD) 15 Table 4: Products under Development by Companies, Graft Versus Host Disease (GVHD) 16 Table 5: Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD) 22 Table 6: Number of Products under Development for Liver Transplant Rejection 23 Table 7: Number of Products under Development by Companies, Liver Transplant Rejection 24 Table 8: Number of Products under Development by Universities/Institutes, Liver Transplant Rejection 25 Table 9: Products under Development by Companies, Liver Transplant Rejection 26 Table 10: Products under Development by Universities/Institutes, Liver Transplant Rejection 27 Table 11: Number of Products under Development for Kidney Transplant Rejection 28 Table 12: Number of Products under Development by Companies, Kidney Transplant Rejection 29 Table 13: Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection 30 Table 14: Products under Development by Companies, Kidney Transplant Rejection 31 Table 15: Products under Development by Universities/Institutes, Kidney Transplant Rejection 33 Table 16: Number of Products under Development for Lung Transplant Rejection 34 Table 17: Number of Products under Development by Companies, Lung Transplant Rejection 35 Table 18: Products under Development by Companies, Lung Transplant Rejection 36 Table 19: Number of Products by Stage and Target, Graft Versus Host Disease (GVHD) 38 Table 20: Number of Products by Stage and Mechanism of Action, Graft Versus Host Disease (GVHD) 41 Table 21: Number of Products by Stage and Route of Administration, Graft Versus Host Disease (GVHD) 45 Table 22: Number of Products by Stage and Molecule Type, Graft Versus Host Disease (GVHD) 46 Table 23: Number of Products by Stage and Target, Liver Transplant Rejection 48 Table 24: Number of Products by Stage and Mechanism of Action, Liver Transplant Rejection 49 Table 25: Number of Products by Stage and Route of Administration, Liver Transplant Rejection 51 Table 26: Number of Products by Stage and Molecule Type, Liver Transplant Rejection 52 Table 27: Number of Products by Stage and Target, Kidney Transplant Rejection 54 Table 28: Number of Products by Stage and Mechanism of Action, Kidney Transplant Rejection 56 Table 29: Number of Products by Stage and Route of Administration, Kidney Transplant Rejection 58 Table 30: Number of Products by Stage and Molecule Type, Kidney Transplant Rejection 59 Table 31: Number of Products by Stage and Target, Lung Transplant Rejection 61 Table 32: Number of Products by Stage and Mechanism of Action, Lung Transplant Rejection 62 Table 33: Number of Products by Stage and Route of Administration, Lung Transplant Rejection 64 Table 34: Number of Products by Stage and Molecule Type, Lung Transplant Rejection 65 Table 35: Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc 66 Table 36: Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International Inc 66 Table 37: Graft Versus Host Disease (GVHD) - Pipeline by Amgen Inc 67 Table 38: Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc 67 Table 39: Graft Versus Host Disease (GVHD) - Pipeline by apceth Biopharma GmbH 68 Table 40: Graft Versus Host Disease (GVHD) - Pipeline by Aptevo Therapeutics Inc 68 Table 41: Graft Versus Host Disease (GVHD) - Pipeline by Athersys Inc 69 Table 42: Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals Inc 70 Table 43: Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc 70 Table 44: Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Co 71 Table 45: Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics Inc 72 Table 46: Graft Versus Host Disease (GVHD) - Pipeline by Cell2B Advanced Therapeutics SA 72 Table 47: Graft Versus Host Disease (GVHD) - Pipeline by Cellect Biotechnology Ltd 72 Table 48: Graft Versus Host Disease (GVHD) - Pipeline by Cellective BioTherapy Inc 73 Table 49: Graft Versus Host Disease (GVHD) - Pipeline by CSL Ltd 73 Table 50: Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Ltd 74 Table 51: Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc 74 Table 52: Graft Versus Host Disease (GVHD) - Pipeline by Elsalys Biotech SA 75 Table 53: Graft Versus Host Disease (GVHD) - Pipeline by enGene Inc 75 Table 54: Graft Versus Host Disease (GVHD) - Pipeline by Enlivex Therapeutics Ltd 76 Table 55: Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd 76 Table 56: Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics Inc 77 Table 57: Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corp Ltd 77 Table 58: Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc 78 Table 59: Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corp 79 Table 60: Graft Versus Host Disease (GVHD) - Pipeline by Inspyr Therapeutics Inc 791.2 List of Figures Figure 1: Number of Products under Development for Graft Versus Host Disease (GVHD) 10 Figure 2: Number of Products under Development by Companies, Graft Versus Host Disease (GVHD) 11 Figure 3: Number of Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD) 14 Figure 4: Number of Products under Development for Liver Transplant Rejection 23 Figure 5: Number of Products under Development by Companies, Liver Transplant Rejection 24 Figure 6: Number of Products under Development by Universities/Institutes, Liver Transplant Rejection 25 Figure 7: Number of Products under Development for Kidney Transplant Rejection 27 Figure 8: Number of Products under Development by Companies, Kidney Transplant Rejection 28 Figure 9: Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection 30 Figure 10: Number of Products under Development for Lung Transplant Rejection 34 Figure 11: Number of Products under Development by Companies, Lung Transplant Rejection 35 Figure 12: Number of Products by Top 10 Targets, Graft Versus Host Disease (GVHD) 37 Figure 13: Number of Products by Stage and Top 10 Targets, Graft Versus Host Disease (GVHD) 37 Figure 14: Number of Products by Top 10 Mechanism of Actions, Graft Versus Host Disease (GVHD) 40 Figure 15: Number of Products by Stage and Top 10 Mechanism of Actions, Graft Versus Host Disease (GVHD) 40 Figure 16: Number of Products by Routes of Administration, Graft Versus Host Disease (GVHD) 44 Figure 17: Number of Products by Stage and Routes of Administration, Graft Versus Host Disease (GVHD) 44 Figure 18: Number of Products by Top 10 Molecule Types, Graft Versus Host Disease (GVHD) 45 Figure 19: Number of Products by Stage and Top 10 Molecule Types, Graft Versus Host Disease (GVHD) 46 Figure 20: Number of Products by Top 10 Targets, Liver Transplant Rejection 47 Figure 21: Number of Products by Stage and Top 10 Targets, Liver Transplant Rejection 47 Figure 22: Number of Products by Top 10 Mechanism of Actions, Liver Transplant Rejection 48 Figure 23: Number of Products by Stage and Top 10 Mechanism of Actions, Liver Transplant Rejection 49 Figure 24: Number of Products by Routes of Administration, Liver Transplant Rejection 50 Figure 25: Number of Products by Stage and Routes of Administration, Liver Transplant Rejection 50 Figure 26: Number of Products by Molecule Types, Liver Transplant Rejection 51 Figure 27: Number of Products by Stage and Molecule Types, Liver Transplant Rejection 52 Figure 28: Number of Products by Top 10 Targets, Kidney Transplant Rejection 53 Figure 29: Number of Products by Stage and Top 10 Targets, Kidney Transplant Rejection 53 Figure 30: Number of Products by Top 10 Mechanism of Actions, Kidney Transplant Rejection 55 Figure 31: Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Transplant Rejection 55 Figure 32: Number of Products by Routes of Administration, Kidney Transplant Rejection 57 Figure 33: Number of Products by Stage and Routes of Administration, Kidney Transplant Rejection 57 Figure 34: Number of Products by Top 10 Molecule Types, Kidney Transplant Rejection 58 Figure 35: Number of Products by Stage and Top 10 Molecule Types, Kidney Transplant Rejection 59 Figure 36: Number of Products by Targets, Lung Transplant Rejection 60 Figure 37: Number of Products by Stage and Targets, Lung Transplant Rejection 60 Figure 38: Number of Products by Mechanism of Actions, Lung Transplant Rejection 61 Figure 39: Number of Products by Stage and Mechanism of Actions, Lung Transplant Rejection 62 Figure 40: Number of Products by Routes of Administration, Lung Transplant Rejection 63 Figure 41: Number of Products by Stage and Routes of Administration, Lung Transplant Rejection 63 Figure 42: Number of Products by Molecule Types, Lung Transplant Rejection 64 Figure 43: Number of Products by Stage and Molecule Types, Lung Transplant Rejection 65

AbbVie Inc AbGenomics International Inc Alexion Pharmaceuticals Inc AnaptysBio Inc Angion Biomedica Corp apceth Biopharma GmbH Aptevo Therapeutics Inc Astellas Pharma Inc Athersys Inc Balmes Transplantation SAS Bellicum Pharmaceuticals Inc Biogen Inc Bioverativ Inc Bristol-Myers Squibb Co Capricor Therapeutics Inc Catalyst Biosciences Inc Cell2B Advanced Therapeutics SA Cellect Biotechnology Ltd Cellective BioTherapy Inc Cynata Therapeutics Ltd Cytodyn Inc Dompe Farmaceutici SpA Elsalys Biotech SA enGene Inc Enlivex Therapeutics Ltd F. Hoffmann-La Roche Ltd Fate Therapeutics Inc Generon (Shanghai) Corp Ltd Gilead Sciences Inc GlaxoSmithKline Plc Hansa Medical AB Idogen AB Incyte Corp Inspyr Therapeutics Inc ITB-Med AB Jazz Pharmaceuticals Plc Kadmon Corp LLC Kamada Ltd Kiadis Pharma NV Kidney Transplant Rejection Kymab Ltd Kyowa Hakko Kirin Co Ltd LG Chem Ltd Liver Transplant Rejection MaaT Pharma Magenta Therapeutics Inc MallInckrodt Plc Medicenna Therapeutics Corp Mesoblast Ltd Millennium Pharmaceuticals Inc Noorik Biopharmaceuticals AG OncoImmune Inc Opsona Therapeutics Ltd Pfizer Inc Pharming Group NV Pluristem Therapeutics Inc Prolong Pharmaceuticals LLC Quark Pharmaceuticals Inc RedHill Biopharma Ltd REGiMMUNE Corp Sanofi Seattle Genetics Inc Seres Therapeutics Inc Shire Plc Sublimity Therapeutics Ltd Syndax Pharmaceuticals Inc Takeda Pharmaceutical Co Ltd Targazyme Inc TC BioPharm Ltd TolerogenixX GmbH United BioPharma Inc Vault Pharma Inc VBI Vaccines Inc Veloxis Pharmaceuticals A/S Visterra Inc Xenikos BV XL-protein GmbH Zai Lab Ltd